HCSD: The human cancer secretome database by Feizi, Amir et al.
Database tool
HCSD: the human cancer secretome database
Amir Feizi1,2, Amir Banaei-Esfahani1 and Jens Nielsen1,2,3,*
1Novo Nordisk Foundation Center for Biosustainability, Department of Biology and Biological
Engineering, Chalmers University of Technology, SE-41296 Go¨teborg, Sweden, 2Novo Nordisk
Foundation Center for Biosustainability, Technical University of Denmark, Fremtidsvej 3, DK-2970
Hørsholm, Denmark and 3Novozymes A/S, Krogshoejvej 36, 2880 Bagsvaerd, Denmark
*Corresponding author: Tel: þ46 31 772 3854; Fax: þ46 31 772 3801; Email: nielsenj@chalmers.se
Citation details: Feizi,A., Banaei-Esfahani,A. and Nielsen,J. HCSD: the human cancer secretome database. Database
(2015) Vol. 2015: article ID bav051; doi:10.1093/database/bav051
Received 23 October 2014; Revised 29 April 2015; Accepted 4 May 2015
Abstract
The human cancer secretome database (HCSD) is a comprehensive database for human
cancer secretome data. The cancer secretome describes proteins secreted by cancer cells
and structuring information about the cancer secretome will enable further analysis of
how this is related with tumor biology. The secreted proteins from cancer cells are
believed to play a deterministic role in cancer progression and therefore may be the key
to find novel therapeutic targets and biomarkers for many cancers. Consequently, huge
data on cancer secretome have been generated in recent years and the lack of a coherent
database is limiting the ability to query the increasing community knowledge. We there-
fore developed the Human Cancer Secretome Database (HCSD) to fulfil this gap. HCSD
contains >80 000 measurements for about 7000 nonredundant human proteins collected
from up to 35 high-throughput studies on 17 cancer types. It has a simple and user
friendly query system for basic and advanced search based on gene name, cancer type
and data type as the three main query options. The results are visualized in an explicit
and interactive manner. An example of a result page includes annotations, cross refer-
ences, cancer secretome data and secretory features for each identified protein.
Database URL: www.cancersecretome.org.
Introduction
Cancer is currently seen as a cluster of complicated diseases
with increasing prevalence globally (1). Understanding and
curing cancer have entered a new phase with the advent of
next generation sequencing and advanced proteomics (2).
In particular, recent advances in both accuracy and scale of
the measurements in proteomics using label-based methods
(such as SILAC and iTRAQ) have revolutionized
oncoproteomics (3). The cancer secretome, as a newly es-
tablished subdiscipline of oncoproteomics, involves the de-
tection, quantification and characterization of the secreted
proteins (such as cytokines, growth factors etc.), shedome
(shed receptors and proteases) and extracellular matrix
components of a given type of cancer cell at a specific time
point (4, 5). Many secreted proteins are linked to the hall-
marks of cancer which are reliant on cell–cell adhesion and
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signaling (6, 7). Much analysis supports how these proteins
in the tumor microenvironment control and regulate the
cancer cell invasion and metastasis (8–11). Along with this,
soluble factors in cancer secretome are promising for novel
biomarkers and therapeutic targets for different types of
cancers (6, 12–16). Accordingly, there has been increasing
number of studies to analyze the cancer secretome resulting
in rapid growth in data generation. For example, Wu and
coworkers identified candidate serological biomarkers for
various cancer types based on secretome analysis of 23
cancer cell lines (17). From 4584 nonredundant proteins
identified in these cancer cell lines, they suggested between
6 and 137 marker candidates selective for each tumor type
and 94 potential pan-cancer markers (proteins secreted by
most cancer cell lines) and they verified several of the iden-
tified protein biomarkers (17). There are many other ex-
amples of the same kind of studies that have provided large
amounts of data to be publically available (18–20).
However, the lack of a specific database for cancer secre-
tome data challenges researchers in the field to query com-
munity knowledge in terms of the time and efficiency.
Therefore, designing a systematic and organized database
to manage large volumes of unstructured cancer secretome
data is in demand. To fulfil this important gap, we de-
signed the Human Cancer Secretome Database (HCSD), a
dynamic database with interactive web interface that pro-
vides the researchers with the opportunity to explore their
protein of interest against the publicly available data on
the human cancer secretome. HCSD has a simple and user-
friendly query system for basic and advanced searches
based on gene name, data type, and cancer type as the
three main query options. The result pages are explicit and
intractable. An example result page includes annotations,
cross references, cancer secretome data and secretory fea-
tures for each protein. Developing HCSD is an important
bioinformatics solution to boost research in cancer secre-
tome and tumor microenvironment.
Materials and methods
Data collection and preprocessing
To collect all relevant data from high-quality publications,
a comprehensive literature survey was done searching the
Scopus and PubMed database starting with the general
keyword ‘cancer secretome’. To avoid accumulation of the
false identifications that is frequent in proteomics data, we
applied stringent selection criteria to filter out publications
including: (i) to have standard workflow of one of the shot-
gun proteomics techniques (with biological and/or tech-
nical replications). (ii) Detailed description for each steps
of the experimental design. (iii) Providing of all the
parameters used in database searching and corresponding
bioinformatics analysis. (iv) Having error estimation strat-
egy (such as FDR). (v) Performing molecular/clinical valid-
ation experiment for the identified biomarkers. (vi)
Providing supplementary detail information tables for
identified portions in peptide and protein level. Applying
these criteria total 35 high-throughput publications were
selected as data source to collect the relevant data (see
DATA SET menu in the web page).
A major concern of any proteomic study is the FDR
(Flase discovery rate) control to prevent from inflation of
false identifications. To obtain reliable results, 1% FDR
should be applied on peptide and protein levels. When
merging distinct datasets, which were analyzed separately,
one has to take special care to avoid inflation of the FDR.
This has been previously done by Schaab et al. (21).
However, to apply such techniques in merging proteomics
datasets, corresponding P values for the reported fold
changes are necessary. Unfortunately, most of the available
data sets have not included the raw data or the P values in
their released data sets. This was a big challenge in design-
ing HCSD, and to overcome to that, we therefore carefully
collected the data based on the cut-off FDR reported in
each paper and we did exclude all the proteins above used
the cut-off. Also, the query results designed to be based on
each study so the user can compare the results from differ-
ent studies on a particular protein of interest and decide
based on major votes. In line with this, we also provided
more technical information on identification such as PSMs
(peptide-spectrum matches) and the number of the unique
peptides match in the results pages for each query. Doing
this while it is not yet possible to fully resolve the inflation
of false identification resulting from combining independ-
ent studies, the results will be reported study wise so the
user can assess the reliability of the results by checking
other supportive information from each study.
Next, the publications were categorized as label-free
and label-based studies based on the proteomics techniques
have been used to quantify the proteome. In label-free
proteomics, the secretome of a specific cancer type is quan-
tified without using a stable isotope containing compound
and the peptide abundance is quantified by spectral count-
ing. On the other hand, in label-based proteomics, stable
isotope(s) is used for labeling and quantification of the
peptides in the comparable samples. The label-based meth-
ods are less sensitive to the experimental biased than label-
free methods (22, 23). Therefore, this categorization helps
user to compare the results from two type of technology.
Because of the difference in publishing the data from one
paper to another, retrieving and processing data tables
from various studies and merging them into a single data-
base structure was time consuming. Missing information










and the format of released data (PDF format) were also
problematic in data collecting step. As most of the studies
only report their data based on gene symbol or protein ID,
for ID mapping, we used bioDBnet (24) to make data be
searchable using different IDs in gene and protein levels. For
each protein in the database the annotation data extracted
from UniProt (25), ensemble (26) and Entrez (27) (Figure 1).
An exclusive link for each record is provided to direct the
user to its HPA cancer atlas (28) page. The HPA page pro-
vides the user with antibody-based protein profiling infor-
mation for the protein of interest in 20 most common
cancers. This allows user to compare the expression status of
the collected proteins in HCSD based on quantitative meth-
ods against antibody-based staining data in HPA.
Databasing and interface design
We used a MYSQL relational database (version 5.5.8) to
design and query HCSD database. The web interface im-
plemented by webpy (www.webpy.org), a python based
web framework. The web.py is in the public domain and it
has been used by Google App Engine. To our knowledge;
this is the first implementation of it in designing a bioinfor-
matics database.It is as powerful as Django (https://www.
Figure 1. The workflow of HCSD design. (a) Appling the selection criteria, first all the cancer secretome data were collected and processed from litera-
tures. (b) Then, I all the complementary annotation and cross references were obtainedfrom UniProt, Ensembl, bioDBnet and Entrez using thethe re-
ported protein or gene IDs in the data tables. (c) Next, the secretory pathway features including signal peptide, transmembrane domains and
nonclassic secretory proteins were predicted using CBS prediction servers (32–34). The secondary structures and PTMs information were retrieved
from UniProt (35). (d) Based on the proteomics strategy used, the secretome data were divided into label-free and label-based studies. (e) The struc-
tured data tables used as input to MySQL to generate searchable data tables by end user (http://www.mysql.com/). (f) For the web server lighttpd is
used to query the database (http://www.lighttpd.net/) and the web application and the interface were implemented using web.py (www.webpy.org),
Javascript (http://en.wikipedia.org/wiki/JavaScript), jQuery (http://jquery.com/) and D3 (http://d3js.org/).










djangoproject.com/) while it is much simpler to implement.
The lighttpd (http://www.lighttpd.net/) were used as a fast
and open source web server which security, speed, compli-
ance and flexibility are all its characteristics comparing to
other competitors. In the query page, two dynamic and
searchable tables for label-free and label-based data were
designed using DataTables plug-in of jQuary (https://
www.datatables.net/). The result pages benefit from high
quality visualization techniques to present the cancer secre-
tome data and secretory features. For visualization,
Javascripts and D3 (www.d3.org) were used upon web.py.
HCSD is available at www.cancersecretome.org.
Querying HCSD
In order to query HCSD data, the user can start with quick
search in the two interactive tables for the label-free and
label-based data based on the gene of interest or informa-
tion in other columns. Also, these tables are sortable for any
columns of interest. We also designed an advanced query
option for the user in order to query the protein/gene of
interest to get more detail information. To do the advanced
query, the user first needs to specify a gene symbol, UniProt
or Ensemble gene ID in the query box. For example, if the
target gene name is EGFR, the user can enter the EGFR in
the query box (the first query field). The integrated auto-
complete feature will let the user to choose the gene name or
IDs in case of uncertainty. Next, the user has to select the
cancer type of interest (or all the cancer types). The last op-
tion is to choose the data type which has three choices- the
label-free, label-based and both options. Then, the user can
submit the query to the server. The advanced query provides
the user the possibility to combine various queries between
the cancer types and quantification techniques. The result
pages of label-free and label-based are similar in annotations
and secretory features section (Figures 3 and 4), but they dif-
fer in secretome data results (Figure 2). For details explan-
ation of the results pages see to the Figures 2–4.
Results
The structure of the HCSD
The HCSD structure was designed to fulfil four main goals
(i) to provide a straightforward searchable depository for
published data on different types of human cancer secre-
tome, (ii) the ability to compare information across differ-
ent secretome measurements (iii) to provide annotation;
cross-references in both gene and protein level for each
data points and (iv) prediction and visualization of the
secretory features for each protein. Therefore, HCSD
contains all the proteins (peptides) that are quantified so
far to be (differentially) expressed in various cancer types
secretome and at the same time provides annotation and
predictions about their secretory type.
In eukaryotic cells, protein secretion is carried out either
by the classic secretion pathway (having N-terminal signal
peptide) or the non-classical pathway(s) (29, 30). It is
valuable to know which processes the detected proteins
potentially use for secretion in to the tumor microenviron-
ment. Beside this, secretome analysis always is contami-
nated with proteins from cell debris or culture media that
results in false identifications. To assist with these chal-
lenges, bioinformatics algorithms have been developed that
can predict the secretory type of proteins from primary se-
quence based on signal peptide pattern, transmembrane
domain or other motifs. These tools are extensively re-
viewed elsewhere (31). However, checking the reliability
of the detection in secretome analysis is tightly depending
on these tools, and therefore a secretory feature section is
included in the results page for each protein query in order
to give a summary of the predictions on signal peptide,
transmembrane domain and nonclassical secretion signals
using the most frequently used bioinformatics tools (Figure
1). Moreover, specific post-translational modifications
(PTMs) are another characteristic of secretory proteins
among which disulphide bonds and glycosylation sites
(N-linked and O-linked) are the most specific. These infor-
mation also can be visualized on protein sequence by the
user in the result page (Figure 5).
An exclusive menu called ‘DATA SETS’ were designed
which allows the user to get access and query the basic in-
formation about the publication used as data source.
Each publication also has its own page which provides
more details on the workflow and experimental design.
The data set table provides hyperlinks to each publication
PubMed page. The study column in the result page also
Figure 2. The Venn diagram of the proteins measured in label-free and
label-based studies (35 publications).










directs the user to PubMed page of the corresponding
publication.
The statistics of the HCSD
From 87 496 total measurements stored in HCSD, 85%
are derived from label-free on 14 cancer types. So far, the
label-based cancer secretome analysis has been mainly per-
formed on 5 cancer types (Supplementary Tables S1 and
S2). The Lung cancer secretome is the most studied cancer
and includes 11% of the total data (Supplementary
Tables S1 and S2). From 7001 unique proteins in HCSD,
6326 are measured in label-free (with 1148 being trans-
membrane proteins) and 4230 being measured in label-
Figure 3. Example of the query page showing the search options.










based (with 534 transmembrane proteins).These two data-
sets share 3555 proteins (Figure 2). In general, most of the
proteins detected in different cancer types secretome are
secreted by nonclassical secretion pathways (Figure S1). In
total, 1413 nonredundant proteins are detected to be se-
creted by classic secretion pathway in 14 cancer types from
21 label-free, while this number for nonclassical secreted
proteins is 4,945. These numbers in label-based studies are
840 (classic) and 3409 (non-classic) proteins (Supplementary
Tables S1 and S2). Most of the cancer secretome data was
generated on cancer cell lines. In 35 publications used to de-
sign HCSD, 70 cancer cell lines were used to study the cancer
secretome (Supplementary Table S3). In case that the authors
did not include the cancer type of the cell lines they used, we
included the corresponding cancer type.
Discussion
How secreted proteins or peptides from cancer cells re-
model the tumor microenvironment in favor of the metas-
tasis is a pivotal research interest in the tumor biology.
Cancer cell secretome profiling is a promising approach to
find potential body fluid-accessible cancer biomarkers and
therapeutic targets, however mining the increasing data
from different labs is a big challenge which affects the effi-
ciency of selecting useful candidates and results in the accu-
mulation of redundant and false identified proteins. HCSD
(www.cancersecretome.org) was developed as a database to
store and query publically available human cancer secre-
tome data to bypass these challenges. It provides the re-
searchers to have access to all the high-throughput data
from studies in this field together with the needed detail
Figure 4. Example from the result pages for label-free and label-based studies. In the result page, the first section (a) provides the annotations such
as gene name, description, chromosomal location and cross references ID to the Ensembl (http://www.ensembl.org/), Entrez (http://www.ncbi.nlm.-
nih.gov/), and UniProt (www.uniprot.org/). In case of label-free search, exploring all type of cancers will be visualized as a table with the cancer type
icons in the header. The first column contains hyperlinked PubMed IDs. For each cancer type column, the protein of interest is detected (green spot),
not detected (red spot) or not studied (grey spot). The last column specify the proteomics method used in the study. (b) In the case of label-based
data, the result table header includes cancer types and the follow up information including the cancer stages, quantified fold change, number of the
PSMs, number of the unique peptides, sequence coverage and body fluid presence will come as additional rows.










information in terms of the functional annotation and secre-
tory type for each protein. It also allows exploring previ-
ously used workflows, cell lines, validated biomarkers and
clinical surveys. HCSD can be used extensively by tumor
biologist to find their target secreted factor in specific or
various cancer types with all the annotations and sequence
bioinformatics analysis of the primary sequence and sec-
ondary structure information of the target proteins. All this
will facilitate the oncoproteomics studies in future.
Supplementary Data
Supplementary data are available at Database Online.
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